Deal facts
- Buyer
- AbbVie Inc.
- Target
- Apogee Therapeutics, Inc.
- Deal value
- USD 10,900,000,000
- Announced
- 18 June 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash
Sources
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
AbbVie Inc. completes acquisition of Apogee Therapeutics, Inc.
Introductory Note As previously disclosed, on June 18, 2026, Apogee Therapeutics, Inc., a Delaware corporation (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Andor LLC, a Delaware limited liability company and a wholly owned subsidiary of Guarantor (“Parent”), Andor Merger Co., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”)
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
TULIP UK BIDCO LIMITED to acquire Spire Healthcare Group plc
TULIP UK BIDCO LIMITED has agreed to acquire Spire Healthcare Group plc in a going private transaction valued at approximately GBP 1.0265 billion. The deal structure inv…
- Buyer
- TULIP UK BIDCO LIMITED
- Target
- Spire Healthcare Group plc
- Deal value
- GBP 1,026,500,000
- Deal type
- going private
CCP PAW 2 LIMITED to acquire ANIMALCARE GROUP PLC
CCP PAW 2 Limited has agreed to acquire Animalcare Group Plc in a going private transaction. The deal was announced and completed on 30 July 2026. Both the buyer and the…
- Buyer
- CCP PAW 2 LIMITED
- Target
- ANIMALCARE GROUP PLC
- Deal value
- Not disclosed
- Deal type
- going private
argenx BV to acquire Forte Biosciences, Inc.
argenx BV and Forte Biosciences, Inc. entered the Exit Mode archive.
- Buyer
- argenx BV
- Target
- Forte Biosciences, Inc.
- Deal value
- USD 2,200,000,000
- Deal type
- going private
Eli Lilly and Company to acquire AtaiBeckley Inc.
Eli Lilly and Company has agreed to acquire AtaiBeckley Inc., a United States-based healthcare firm, in a going private transaction. The deal was announced on 15 July 20…
- Buyer
- Eli Lilly and Company
- Target
- AtaiBeckley Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Vertex Pharmaceuticals Incorporated to acquire Crinetics Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc. entered the Exit Mode archive.
- Buyer
- Vertex Pharmaceuticals Incorporated
- Target
- Crinetics Pharmaceuticals, Inc.
- Deal value
- USD 10,000,000,000
- Deal type
- going private
Buyer history
AbbVie Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive